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In England, UK, hospital admissions caused by bacterial 
infections associated with opioid use have increased annu-
ally since 2012, after 9 years of decline, mirroring trends in 
overdose deaths. The increase occurred among persons of 
both sexes and in all age groups and suggests preventive 
measures need reviewing.
In the United Kingdom, opioid overdose deaths have in-creased substantially, linked to increasing purity of street 
heroin and an aging cohort of persons who inject drugs 
(PWID) (1). PWID also are at risk for skin, soft tissue, and 
vascular infections (SSTVI), and one third of PWID in the 
United Kingdom report symptoms of an injection-site in-
fection within the previous year (2). Outbreaks and clus-
ters of bacterial infections among PWID are documented 
in the United Kingdon (3,4). Most infections are caused by 
staphylococci and other commensal gram-positive bacteria 
entering the body at injecting sites. Abscesses and phlebitis 
are common (5,6) and can lead to invasive infections. Data 
from a London hospital suggest that such skin and soft tis-
sue infections cause 58% of hospital admissions in PWID, 
and treatment typically costs several times more than in-
fections in other groups (5). Because little is known about 
SSTVI trends among PWID over time, we used routine 
data from all National Health Service hospitals in England 
to describe hospital admissions for this group.
The Study
We used the Hospital Episode Statistics for England da-
taset and included all admissions from April 5, 1997, 
through April 4, 2016, for patients 15–55 years of age. 
As the most common injecting-related problems (6), we 
included admissions with a primary (or first-listed) cause 
of cutaneous abscess (International Classification of Dis-
eases, Tenth Revision, code L02*), cellulitis (L03*), and 
phlebitis or thrombophlebitis (I80*). We also included 
admissions where the first-listed cause was endocarditis 
(I011, I39*, I330, 1400, I410), septicemia (A40*, A41*), 
osteomyelitis or septic arthritis (M86*, M00*, M465), 
or necrotizing fasciitis (M762) and grouped these as in-
vasive infections. Because patients might have multiple 
episodes of care within 1 admission, we included only 
first episodes. Age, sex, year of admission, all diagnostic 
fields, and duration of admission were extracted. Public 
Health England provided the data.
Hospital Episode Statistics do not report whether a 
patient injects drugs. Previous studies have identified pa-
tients who use drugs as those with a drug-related diag-
nosis in any diagnostic field (7,8). We identified patients 
with “injecting-related” infections as those with a rele-
vant infection in the primary diagnostic field and “mental 
and behavioral disorders due to opioid use” (F11*) in any 
other diagnostic field, because most PWID in the United 
Kingdom inject an opioid (9). 
We counted injecting-related and non–injecting-relat-
ed admissions and stratified them by year and patient sex 
and age group (15–34, 35–44, and 45–55 years). We also 
tested whether injecting-related infections were associated 
with longer hospitalization by using a zero-inflated negative 
binomial model (10) (online Technical Appendix, https://
wwwnc.cdc.gov/EID/article/23/8/17-0439-Techapp1.pdf).
During 1997–2016, a total of 1,052,444 hospital ad-
missions were caused by SSTVIs, of which 63,671 (6%) 
were injecting-related. One third (35%) of injecting-related 
admissions had a primary cause of cutaneous abscess, 32% 
phlebitis, 23% cellulitis, 4% septicemia, 4% osteomyelitis 
or septic arthritis, 2% endocarditis, and 0.2% necrotizing 
fasciitis. Patients with injecting-related infections were 
younger and more likely to live in deprived neighborhoods, 
and a minority were female (Table).
The number of injecting-related admissions increased 
by 33% per year (compound annual growth rate) from 
1997–98 through 2003–04 (Figure 1); relative increases 
were similar in each age group. The total number then de-
creased each year from 2003–04 through 2012–13; rela-
tive changes differed by age group. Admissions reduced 
by 15% per year for 15–34-year-olds, remained approxi-
mately constant for 35–44-year-olds, and increased by 
5% per year for 45–55-year-olds. From 2012–13 through 
2015–16, the total number of injecting-related admissions 
increased each year in all age groups. The largest rela-
tive increase was for 45–55-year-olds (18% per year). The 
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number of non–injecting-related admissions increased 
throughout the period; relative increases were similar for 
each age group and for men and women (online Technical 
Appendix Figure 1).
As a sensitivity analysis, we excluded admissions 
within 7 days after discharge, which totaled 4,389 (7%) 
injecting-related admissions. This exclusion did not change 
the overall trend (online Technical Appendix).
Injecting-related admissions were longer than non–in-
jecting-related admissions. The difference varied by cause 
of admission; differences were larger for admissions caused 
by cutaneous abscess or by invasive infections (Figure 2).
Conclusions
Our analysis of hospital data shows a substantial increase 
in episodes of serious infection among PWID since 2012. 
Increases occurred in all age groups and for both men and 
women. Community surveys have not indicated such a 
large increase in the prevalence of symptoms of injection-
site infections (9), suggesting that the increase might be 
confined to more severe infections.
The temporal trend found here for bacterial infections 
mirrors that for opiate overdose–related deaths in England 
and Wales, which increased sharply from the early 1990s 
until 2001, decreased gradually until 2012, and then in-
creased again (1). Explanations given for the recent in-
crease in overdoses include an aging cohort of PWID, 
increasing purity of street heroin, and an increased focus 
by addiction services on treatment completions, includ-
ing reducing the number of patients on long-term opioid 
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Table. Demographic characteristics of patients with skin, soft 
tissue, and vascular infections, England, UK, April 5, 1997–April 
4, 2016* 
Characteristic 
Patients with 
injecting-related 
infections 
Patients with 
non–injecting-
related infections 
Median age, y (IQR)   
 All 34 (29–39) 40 (30–48) 
  M 34 (30–40) 40 (31–48) 
  F 32 (27–37) 39 (29–48) 
 By year   
  2000–01 31 (27–36) 39 (30–48) 
  2005–06 32 (28–37) 39 (30–47) 
  2010–11 35 (30–41) 40 (30–48) 
  2015–16 38 (33–43) 41 (30–49) 
Female sex, %   
 All 28 44 
 By age group, y   
  15–34 32 45 
  35–44 23 42 
  45–54 22 43 
Neighborhood deprivation quintile, %  
 1 (least deprived) 5 21 
 2 10 21 
 3 16 20 
 4 25 20 
 5 (most deprived) 44 19 
*Selected years are shown for brevity. Patients with injecting-related 
infections were younger for both sexes and in each year (p<0.001, 
Wilcoxon rank-sum tests). A smaller proportion of patients with injecting-
related infections were female for all age groups (p<0.001, 2 tests). Age 
group was associated with sex for both injecting-related and non–injecting-
related infections (p<0.001, 2 tests). A linear trend described the 
proportion of injecting-related admissions in each deprivation quintile 
better than no trend (p = 0.009) but not for non–injecting-related admission 
(p = 0.504). Neighborhood deprivation was the UK Department for 
Community and Local Government’s Index of Multiple Deprivation 2004. 
IQR, interquartile range. 
 
Figure 1. Number of hospital admissions caused by injecting-related bacterial infections, by age group, England, UK, April 5, 1997–April 
4, 2016.
DISPATCHES
substitution therapy (1,11). These factors also might con-
tribute to the increase in bacterial infections. Older PWID 
may lose venous access; miss veins more often when try-
ing to inject (12); and use less accessible and more heav-
ily colonized injection sites, such as the femoral vein (13), 
leading to more infections. These persons also might have 
worse immunity and poorer underlying health. An aging 
cohort of PWID is unlikely to explain the entire increase, 
however, because increases occurred in all age groups. 
The role of changes to addiction services and street heroin 
purity are potential areas for further research.
Additional factors might be contributing to the in-
crease. Opiate users may have started to inject recently 
emerged psychoactive drugs, which are associated with 
increased risk for serious bacterial infection (14), although 
the injection of these drugs remains relatively uncommon 
in the United Kingdom (9). Primary care services might 
have become less accessible to PWID, leading to a greater 
proportion of infections becoming serious and requiring 
hospitalization. In London, drug preparation using citric 
acid has been documented to result in highly acidic heroin 
mixtures (15), potentially precipitating venous damage and 
infections. Finally, the increase in infections could indicate 
that the population of PWID has grown since 2012, but 
little evidence exists with which to test this possibility.
A limitation of our study is that Hospital Episode 
Statistics do not record whether patients inject drugs, and 
therefore a proxy was used. The data are likely to underes-
timate the true number of SSTVI in PWID because hospi-
tals might not always include the opioid-related diagnostic 
code when PWID are admitted.
Illnesses and deaths from bacterial infections in PWID 
are more difficult to measure than overdoses because bacte-
rial infections are not specific to drug use. The increasing 
number of serious infections shown by these data suggests 
a need for more active surveillance. Preventive measures 
also need to be considered, including improving access and 
adherence to wound care and antimicrobial drug regimens, 
reducing the acidity of heroin preparations, and ensuring 
accessibility of opioid substitution therapy and sterile in-
jecting equipment.
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